Skip to content

Hyperbaric Oxygen Therapy for Peripheral Neuropathy Due to Paclitaxel Analogs

Hyperbaric Oxygen Therapy for Peripheral Neuropathy Due to Paclitaxel Analogs

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06819501
Enrollment
226
Registered
2025-02-11
Start date
2025-02-05
Completion date
2026-09-01
Last updated
2025-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancers

Brief summary

The goal of this study was to explore the safety and efficacy of hyperbaric oxygen in the treatment of peripheral neuropathy due to paclitaxel analogues

Interventions

DEVICEhyperbaric oxygenation treatment

Administration of 100% oxygen at a pressure of 2.0ATA once daily for 60-90 minutes for a total of 30-40 times.

BEHAVIORALroutine care

Administration of pressurised ice gloves 30 minutes before, during, and 30 minutes after administering paclitaxel chemotherapy drugs.

Sponsors

Guangdong Provincial People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Patients with newly diagnosed breast cancer by pathology 2. Age 18-60 years 3. ECOG 0-2 4. CIPN patients with NCI-CTCAE grade 1 or higher after treatment with paclitaxel-based drugs

Exclusion criteria

1. Patients with contraindications to hyperbaric oxygen i. Untreated pneumothorax. ii. concomitant administration of disulfiram. iii. concomitant administration of antineoplastic drugs such as bleomycin, cisplatin, adriamycin. iv. premature and/or low body mass newborns. iv. Premature and/or low body mass neonates. 2. Other cancers

Design outcomes

Primary

MeasureTime frameDescription
Difference in change in CIPN score due to paclitaxel analogues compared to baselineBaseline, 2 week, 4 week, 6 week, 8 weekDifference in change in CIPN score due to paclitaxel analogues compared to baseline

Secondary

MeasureTime frameDescription
EORTC QLQ - CIPN20Baseline, 2 week, 4 week, 6 week, 8 week
ENS scoreBaseline, 2 week, 4 week, 6 week, 8 week
neuromyographyBaseline, 8 week
life qualityBaseline, 2 week, 4 week, 6 week, 8 weekFACT-B Quality of Life Score
NPS degreeBaseline, 2 week, 4 week, 6 week, 8 week
depression scoreBaseline, 2 week, 4 week, 6 week, 8 weekHospital Anxiety and Depression Scale (HADS)
Exhaustion scoreBaseline, 2 week, 4 week, 6 week, 8 weekBrief Fatigue Inventory (BFI)
Side effects of hyperbaric oxygen therapyduring the hyperbaric oxygen therapy (up to 2 months)
insomnia scoreBaseline, 2 week, 4 week, 6 week, 8 weekInsomnia Severity Index (ISI)

Countries

China

Contacts

Primary ContactKun wang, Professor
gzwangkun@126.com86+13829694500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026